Acorda Therapeutics (ACOR) Tops Q1 EPS by 38c, Revenues Beat
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/18/2026
- Tech selloff pulls Wall Street to two-week lows as bond yields climb
- Baidu slips as Q2 results miss estimates despite growth in AI cloud business
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Home Depot beats estimates, reaffirms fiscal 2026 guidance
- Citi says positioning risk is shifting from short squeezes to profit-taking
- Wall Street indexes slip as oil prices rise, retail results awaited
- Micron rises as White House presses Apple to avoid Chinese memory chips
- BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
- Tech selloff pulls Wall Street to two-week lows as bond yields climb
- Francisco Partners to acquire Weave Communications for $650M
Acorda Provides Update for First Quarter Ended March 31, 2019
May 2, 2019 6:00 AM EDTINBRIJA (levodopa inhalation powder) commercially available on February 28; first and only FDA-approved inhaled levodopa for intermittent treatment of OFF episodes in people with Parkinsons taking carbidopa/levodopa INBRIJA 1Q 2019 net sales of $1.3 million; approximately 2,000 prescription request forms received through April 2019 AMPYRA® (dalfampridine) 1Q 2019 net sales of $40.1 million
ARDSLEY, N.Y.--(BUSINESS WIRE)-- Acorda Therapeutics, Inc. (NASDAQ:... More
